Pharmaceutical - AstraZeneca

Filter

Current filters:

AstraZeneca

Popular Filters

301 to 314 of 314 results

AstraZeneca offering Arimidex for just $40 a month in USA

16-02-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has launched what it says is its first-ever direct-to-patient…

ArimidexAstraZenecaMarkets & MarketingNorth AmericaOncologyPharmaceuticalPricing

AstraZeneca profits rise, but more jobs to go

02-02-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning unveiled a set of financial results for…

AstraZenecaFinancialPharmaceutical

Impax buys US rights to Zomig

01-02-2012

Impax Pharmaceuticals, the branded products business unit of Impax Laboratories (Nasdaq: IPXL) has licensed…

AstraZenecaImpax LaboratoriesLicensingMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalZomig

FDA’s CRL on dapagliflozin calls for more clinical data

19-01-2012

In what comes as no surprise given a negative vote by an Food and Drug Administration advisory panel…

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesNorth AmericaPharmaceuticalRegulation

Japanese approval for Regnite and Ranmark

18-01-2012

Japanese drug major Astellas Pharma (TYO: 4503) and USA-based XenoPort (Nasdaq: XNPT) revealed yesterday…

AmgenAsia-PacificAstellas PharmaAstraZenecaBiotechnologyDaiichi SankyodenosumabFinancialNeurologicalOncologyPharmaceuticalRanmarkRegniteRegulationXenoPort

AstraZeneca links with IMS on real-world evidence

11-01-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered into a three-year collaboration agreement…

AstraZenecaEuropeHealthcarePharmaceuticalResearch

Mixed NICE views on Faslodex and RoActemra

14-12-2011

There was mixed news this morning from the UK’s National Institute for Health and Clinical Excellence…

Anti-Arthritics/RheumaticsAstraZenecaEuropeFaslodexOncologyPharmaceuticalPricingRegulationRoActemraRoche

AstraZeneca sells imaging agent rights

13-12-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has out-licensed AZD4694, its late-stage radiopharmaceutical…

AstraZenecaLicensingNeoprobeNeurologicalPharmaceutical

AstraZeneca expands in China, cuts back in USA

08-12-2011

It was a busy couple of days for Anglo-Swedish drug major AstraZeneca (LSE: AZN), with the company yesterday…

Asia-PacificAstraZenecaGenericsGuangdong BeiKang PharmaManagementMergers & AcquisitionsNorth AmericaPharmaceutical

AstraZeneca unlocks medical research cupboard to academia, as UK plans boost for pharma sector

05-12-2011

In a ground-breaking scientific collaboration, Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning…

AstraZenecaEuropeFinancialPharmaceuticalResearch

Brazilian acute coronary syndrome drug market set to nearly double to $229 million in 2015

01-12-2011

The acute coronary syndrome (ACS) drug market in Brazil will nearly double from $122 million in 2010…

AstraZenecaBrilintaCardio-vascularEffientEli LillyMarkets & MarketingPharmaceuticalSouth America

Further $100 million committed to AstraZeneca’s MedImmune Ventures

29-11-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed yesterday that it has committed an additional…

AstraZenecaFinancialMedImmuneMergers & AcquisitionsPharmaceutical

EC approves additional use for Bristol-Myers and AstraZeneca’s Onglyza and Komboglyze

29-11-2011

The European Commission has approved drug majors Bristol-Myers Squibb (NYSE: BMY) and AstraZeneca’s…

AstraZenecaBristol-Myers SquibbDiabetesEuropeKomboglyzeOnglyzaPharmaceuticalResearch

301 to 314 of 314 results

Parexel

Parexel

Back to top